Ultrapotent Inhibitor of Clostridioides difficile Growth, Which Suppresses Recurrence In Vivo.
Ultrapotent Inhibitor of Clostridioides difficile Growth, Which Suppresses Recurrence In Vivo.
复制标题
DOI:
10.1021/acs.jmedchem.0c01198
复制
发表时间:
2020-10-22
影响因子:
7.3
通讯作者:
Sintim, Herman O.
中科院分区:
文献类型:
--
作者:
Naclerio, George A.;Abutaleb, Nader S.;Li, Daoyi;Seleem, Mohamed N.;Sintim, Herman O.
Clostridioides difficile (C. difficile) is the leading cause of healthcare-associated infection in the U.S. and considered an urgent threat by the Centers for Disease Control and Prevention (CDC). Only two antibiotics, vancomycin and fidaxomicin, are FDA-approved for the treatment of C. difficile infection (CDI) but these therapies still suffer from high treatment failure and recurrence. Therefore, new chemical entities to treat CDI are needed. Trifluoromethylthio containing N-(1,3,4-oxadiazol-2-yl)benzamides displayed very potent activities (sub-μg/mL minimum inhibitory concentration (MIC) values) against Gram-positive bacteria. Here, we report remarkable antibacterial activity enhancement via halogen substitutions, which afforded new anti-C. difficile agents with ultrapotent activities (MICs as low as 0.003 μg/mL (0.007 μM)) that surpassed the activity of vancomycin against C. difficile clinical isolates. The most promising compound in the series, HSGN-218, was non-toxic to mammalian colon cells and is gut restrictive. In addition, HSGN-218 protected mice from CDI recurrence. Not only does this work provide a potential clinical lead for the development of C. difficile therapeutics but also it highlights dramatic drug potency enhancement via halogen substitution.
登录
查看更多内容
影响因子:
6.7
作者:
Chumbler NM;Farrow MA;Lapierre LA;Franklin JL;Haslam DB;Goldenring JR;Lacy DB
通讯作者:
Lacy DB
影响因子:
7.3
作者:
Hammad, Ali;Abutaleb, Nader S.;Mayhoub, Abdelrahman S.
通讯作者:
Mayhoub, Abdelrahman S.
影响因子:
24.5
作者:
BOLTON, RP;CULSHAW, MA
通讯作者:
CULSHAW, MA
影响因子:
3
作者:
Gentry, CL;Egleton, RD;Davis, TP
通讯作者:
Davis, TP
影响因子:
4.6
作者:
Daina A;Michielin O;Zoete V
通讯作者:
Zoete V